Recombinant α2(IV)NC1 domain of type IV collagen is an effective regulator of retinal capillary endothelial cell proliferation and inhibits pre-retinal neovascularisation

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 245, Issue 4, 2007, Pages 581-587

  Coleman, Gary ^a   Gardiner, Tom A ^a   Boutaud, Ariel ^b   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BioStratum Incorporated   (United States)

Author keywords

(2(IV)NC1; Neovascularisation; Proliferative retinopathy; Retinal microvascular endothelium

Indexed keywords

BROXURIDINE; CANSTATIN; DNA; COLLAGEN TYPE 4; OXYGEN; RECOMBINANT PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIUM; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DNA REPLICATION; DRUG EFFICACY; EPITHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REGULATORY MECHANISM; RETINA BLOOD VESSEL; RETINA CAPILLARY; RETINA NEOVASCULARIZATION; ANIMAL; C57BL MOUSE; CAPILLARY; CATTLE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; NEWBORN; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; VASCULAR ENDOTHELIUM;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CAPILLARIES; CATTLE; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; MICE, INBRED C57BL; OXYGEN; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS;

EID: 33947608070     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0396-1     Document Type: Article

References (39)

1. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028
2. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598
3. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571
4. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
5. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92:391-400
6. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822
7. Chakravarthy U, Gardiner TA, Anderson P, Archer DB, Trimble ER (1992) The effect of endothelin 1 on the retinal microvascular pericyte. Microvasc Res 43:241-254
8. Christoffersen NL, Larsen M (1999) Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 106:2054-2062
9. Coats DK, Miller AM, Brady McCreery KM, Holz ER, Paysse EA (2004) Involution of threshold retinopathy of prematurity after diode laser photocoagulation. Ophthalmology 111:1894-1898
10. Colorado PC, Torre A, Kamphaus G, Maeshima Y, Hopfer H, Takahashi K, Volk R, Zamborsky ED, Herman S, Sarkar PK, Ericksen MB, Dhanabal M, Simons M, Post M, Kufe DW, Weichselbaum RR, Sukhatme VP, Kalluri R (2000) Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60:2520-2526
11. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S (1998) Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 95:11211-11216
12. Donaldson EA, McKenna DJ, McMullen CB, Scott WN, Stitt AW, Nelson J (2000) The expression of membrane-associated 67-kDa laminin receptor (67LR) is modulated in vitro by cell-contact inhibition. Mol Cell Biol Res Commun 3:53-59
13. Erickson AC, Couchman JR (2000) Still more complexity in mammalian basement membranes. J Histochem Cytochem 48:1291-1306
14. Fenton BM, Paoni SF, Ding I (2004) Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 72:221-230
15. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 93:9764-9769
16. Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13:555-562
17. Gargiulo P, Giusti C, Pietrobono D, La Torre D, Diacono D, Tamburrano G (2004) Diabetes mellitus and retinopathy. Dig Liver Dis 36(Suppl 1):S101-S105
18. Gebarowska D, Stitt AW, Gardiner TA, Harriott P, Greer B, Nelson J (2002) Synthetic peptides interacting with the 67-kd laminin receptor can reduce retinal ischemia and inhibit hypoxia-induced retinal neovascularization. Am J Pathol 160:307-313
19. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3:589-601
20. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2:529-533
21. Hikichi T, Nomiyama G, Ikeda H, Yoshida A (1999) Vitreous changes after treatment of retinopathy of prematurity. Jpn J Ophthalmol 43:543-545
22. Hudson BG, Reeders ST, Tryggvason K (1993) Type IV collagen: Structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. J Biol Chem 268:26033-26036
23. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, Torre A, Maeshima Y, Mier JW, Sukhatme VP, Kalluri R (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275:1209-1215
24. King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS (1997) Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Mol Cell Biol 17:4406-4418
25. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA (1996) Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest 75:563-573
26. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R (2000) Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275:21340-21348
27. Panka DJ, Mier JW (2003) Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 278:37632-37636
28. Paulsson M (1992) Basement membrane proteins: Structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 27:93-127
29. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, Ninomiya Y, Sarras MP Jr, Hudson BG, Brooks PC (2000) New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 275:8051-8061
30. Repka MX, Palmer EA, Tung B (2000) Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 118:645-649
31. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjic N (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556-20567
32. Shiojima I, Walsh K (2002) Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90:1243-1250
33. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101-111
34. Stitt AW, Graham D, Gardiner TA (2004) Ocular wounding prevents pre-retinal neovascularization and upregulates PEDF expression in the inner retina. Mol Vis 10:432-438
35. Stitt AW, Hughes SJ, Canning P, Lynch O, Cox O, Frizzell N, Thorpe SR, Cotter TG, Curtis TM, Gardiner TA (2004) Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 47:1735-1746
36. Stitt AW, McGoldrick C, Rice-McCaldin A, McCance DR, Glenn JV, Hsu DK, Liu FT, Thorpe SR, Gardiner TA (2005) Impaired retinal angiogenesis in diabetes: Role of advanced glycation end products and galectin-3. Diabetes 54:785-794
37. Stitt AW, McKenna D, Simpson DA, Gardiner TA, Harriott P, Archer DB, Nelson J (1998) The 67-kd laminin receptor is preferentially expressed by proliferating retinal vessels in a murine model of ischemic retinopathy. Am J Pathol 152:1359-1365
38. Sundaramoorthy M, Meiyappan M, Todd P, Hudson BG (2002) Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes. J Biol Chem 277:31142-31153
39. Zarzag D, Shiff B, Jallo GI, Greco MA, Blaco C, Cohen H. Hukin J, Allen JC, Friedlander DR (2002) Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase, Cancer Res 62:2660-2668